EMEA-003512-PIP01-23 - paediatric investigation plan
tifcemalimab
PIPHuman
Key facts
- Active Substance
- tifcemalimab
- Therapeutic area
- Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- Decision number
- P/0016/2024
- PIP number
- EMEA-003512-PIP01-23
- Pharmaceutical form(s)
- All pharmaceutical forms
- Condition(s) / indication(s)
- Treatment of lung cancer (small cell and non-small cell lung cancer)
- Route(s) of administration
- All routes of administration
- Contact for public enquiries
E-mail: regulatory@topalliancebio.com
Tel. +13 016 405 166
- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date